HIIQ, AVEO & CVS Bronstein, Gewirtz & Grossman, LLC Class Action Reminder

NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Health Insurance Innovations, Inc. HIIQ

Class Period: February 28, 2018 - November 27, 2018

Deadline: April 22, 2019

For more info: www.bgandg.com/hiiq

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) a substantial portion of Health Insurance Innovations' revenue was derived from third parties; (2) these third parties used deceptive tactics to sell Health Insurance Innovations' policies, including overstating the policy's coverage and/or selling under the licenses of employees who had no involvement in the underlying sales; (3) regulatory scrutiny of these third parties would materially impact Health Insurance Innovations' operations; and (4) as a result of the foregoing, defendants' positive statements about Health Insurance Innovations' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. 

AVEO Pharmaceuticals, Inc. AVEO

Class Period: August 4, 2016 - January 31, 2019

Deadline: April 26, 2019

For more info: www.bgandg.com/aveo

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO's lead candidate drug, tivozanib, from the TIVO-1 trial presented in the June 2013; (2) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (3) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (4) as a result, AVEO's public statements were materially false and misleading at all relevant times. 

CVS Health Corporation CVS

Class Period: May 21, 2015 - February 20, 2019

Deadline: April 26, 2019

For more info: www.bgandg.com/cvs

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) CVS Health's financial condition and expected earnings were deteriorating as a result of rising costs and poor results associated with the Omnicare Acquisition; and (2) as a result, CVS Health's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com